A recent groundbreaking study led by researchers at NYU Langone Health has unveiled the detrimental effects of prior authorization requirements on the timely access to essential heart failure medications. The study focuses on two pivotal classes of drugs, angiotensin receptor-neprilysin inhibitors (ARNIs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors, both of which are integral to contemporary heart failure management but lack generic alternatives and incur substantial out-of-pocket expenses for patients. These findings reveal a significant delay and, in many cases, complete abandonment of prescriptions due to insurer-mandated prior authorization protocols, which demand clinicians secure insurance approval before medications are covered.
The research scrutinized prescription fill patterns among 2,183 heart failure patients within the NYU Langone Health system between 2021 and 2023. By analyzing electronic health records alongside pharmacy fill logs, the team identified that prior authorization prolonged the median fill time by a factor of three for ARNIs and six for SGLT2 inhibitors compared to prescriptions exempt from such requirements. Notably, patients prescribed SGLT2 inhibitors under prior authorization mandates were twice as likely to never initiate therapy. Such delays are alarming given the robust evidence indicating these drugs’ capability to markedly reduce mortality when incorporated into standard treatment regimens for heart failure.
Cardiologist Amrita Mukhopadhyay, MD, the study’s principal investigator, emphasizes the paradoxical impact of prior authorization policies. While initially intended to curb healthcare costs by controlling drug utilization, they inadvertently impose access barriers to life-saving medications without generic alternatives. This obstruction is particularly concerning in conditions like heart failure, where prompt therapeutic intervention is critical to improving survival outcomes. Dr. Mukhopadhyay suggests that these bureaucratic hurdles may compromise the continuity and efficacy of essential care.
The study provides a mechanistic insight into how prior authorization protocols disrupt patient behavior and clinical decision-making. Most heart failure patients fill their prescriptions on the same day as their medical appointment; however, pharmacies frequently inform patients that their medications will not be available until weeks later due to insurer requirements. Such delays not only dissuade patients from completing the fill process but may also cause clinicians to avoid prescribing these optimal therapies preemptively, anticipating the administrative burden. This behavioral feedback loop underscores the systemic challenges imposed by insurance-driven regulations.
Furthermore, the investigators highlight the broader implications of health disparities perpetuated by these policies. Analysis revealed that prior authorization requirements disproportionately affected patients residing in lower socioeconomic neighborhoods and those identifying as Black or Hispanic. Additionally, individuals covered by Medicaid were more frequently subjected to these barriers. These findings amplify concerns that prior authorization may exacerbate existing inequities in heart failure care access, disproportionately impacting traditionally marginalized groups and compounding health outcome disparities.
Senior author Saul Blecker, MD, stresses the urgency of reevaluating prior authorization practices within the context of equitable healthcare delivery. The systemic delay and limited medication access not only undermine clinical guidelines but also risk widening the health divide encountered by vulnerable populations. Dr. Blecker underscores the necessity of policy reforms that reconcile cost containment strategies with optimized patient-centered care, ensuring that life-saving medications are accessible without undue obstruction.
The study leveraged rigorous statistical methodologies, adjusting for demographic variables including race, ethnicity, gender, education level, and other social determinants, thus reinforcing the validity and generalizability of its conclusions within the study population. While acknowledging limitations—such as confinement to a single healthcare system and New York state’s comparatively comprehensive Medicaid coverage—the authors caution that barriers elsewhere in the United States may be even more pronounced, calling for extended investigations across diverse healthcare environments.
This research is the first to provide quantifiable evidence linking prior authorization mandates specifically to delayed pharmacy fills and prescription abandonment of ARNI and SGLT2 inhibitors among heart failure patients. By elucidating this causal relationship, the study advances the discourse on how insurance mechanisms directly impact clinical outcomes and patient adherence, challenging stakeholders to reconcile economic policies with patient welfare imperatives.
The investigative team plans to expand their inquiry into additional insurance-related factors such as co-payments and coinsurance, which may further influence patients’ accessibility to these vital medications. Understanding the multifaceted dimensions of insurance structures is critical to devising comprehensive strategies that ensure adherence to pharmacologic guidelines and mitigate avoidable morbidity and mortality in heart failure.
The findings resonate with prior qualitative research that has documented clinician and patient frustrations with prior authorization processes, which often contribute to treatment delays, non-adherence, and diminished trust in the healthcare system. By substantiating these concerns with empirical data, the study calls for urgent healthcare policy reforms to remove unnecessary bureaucratic obstacles for medications proven to improve survival.
Funding for this important work was provided by several grants from the National Institutes of Health (NIH) and support from the American Heart Association and New York Academy of Medicine, underscoring the high scientific and public health value attributed to this issue. It offers a clarion call to healthcare providers, insurers, policymakers, and patient advocates to critically appraise and streamline authorization protocols, fostering equitable, prompt, and effective treatment for heart failure patients nationwide.
As heart failure continues to impose a significant burden on global public health, strategies ensuring unimpeded access to cutting-edge therapies like ARNIs and SGLT2 inhibitors are paramount. This study highlights how current insurance policy implementations jeopardize optimal care delivery and exacerbate disparities, emphasizing the need for systemic change bolstered by data-driven evidence and empathetic patient engagement.
Subject of Research: People
Article Title: Prior Authorization Requirements and Prescription Fill Patterns Among Patients With Heart Failure
News Publication Date: 27-Jan-2026
Web References: http://dx.doi.org/10.1016/j.jacadv.2025.102583
Keywords: Health insurance, Heart failure, Health disparity
Tags: ARNI heart failure treatment barrierselectronic health records in heart failure researchheart failure patient treatment adherenceimpact of insurance approval on drug accessinsurer mandates and prescription delaysmedication abandonment due to prior authorizationNYU Langone Health heart failure studyout-of-pocket costs for heart failure drugsprior authorization delays heart failure medicationreducing mortality with heart failure medicationsSGLT2 inhibitors prescription challengestimely access to life-saving cardiac drugs
